F-star Therapeutics, Inc. FSTX
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 156.51M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.07
- Beta
- -0.35
- Short ratio
- 2.59
- Inst. own
- 44.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 13, 2023
- 50-d avg
- 5.63
- 200-d avg
- 5.74
- 1y target
- 7.00
Key statistics
- Market cap
- 156.51M
- Enterprise value
- 133.62M
- Trailing P/E
- 0.00
- Forward P/E
- -2.07
- PEG ratio
- 0.00
- Price / sales
- 7.39
- Price / book
- 2.75
- EPS (TTM)
- -1.83
- Beta
- -0.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -211.32%
- Revenue (TTM)
- 21.18M
- Revenue growth
- 49.80%
- Free cash flow
- -20.46M
- Total cash
- 35.57M
- Total debt
- 12.68M
- Return on equity
- -60.87%
- Shares outstanding
- 21.98M
- Short % of float
- 5.64%
- 50-day average
- 5.63
- 200-day average
- 5.74
Analyst view
Consensus: hold
Next earnings
Mar 13, 2023
Expected Mar 13, 2023. Consensus EPS estimate -0.39.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 13, 2023 | Dec 1, 2022 | -0.55 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.69 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.62 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.63 | — | — | — |
| Mar 14, 2022 | Dec 1, 2021 | -0.43 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.56 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 24, 2022 | SVB Leerink | down | Outperform | Market Perform |
| May 11, 2022 | SVB Leerink | main | — | Outperform |
| Mar 17, 2022 | HC Wainwright & Co. | init | — | Buy |
| Aug 17, 2021 | SVB Leerink | main | — | Outperform |
| Jul 8, 2021 | SVB Leerink | init | — | Outperform |
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- f-star.com
News
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
- Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
- Earnings Scheduled For May 10, 2022
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Friday
- Earnings Scheduled For November 10, 2021
Your note
Sign in to keep a note on FSTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENZ EDWARD J. JR | Director | Stock Award(Grant) | Jan 31, 2021 | 4,385 |
| BERMINGHAM NESSAN | Director | Stock Award(Grant) | Jan 31, 2021 | 103,875 |
| BREWIS NEIL | Officer | Conversion of Exercise of derivative security | Jul 28, 2022 | 114,463 |
| DEPTULA-HICKS DARLENE M | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2021 | 56,437 |
| DRISCOLL MARTIN J | Chief Executive Officer | Sale | Nov 19, 2020 | 47,425 |
| FORSTER ELIOT | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 28, 2022 | 421,537 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.55% | 1,000,000 | 7.12M | Dec 30, 2022 |
| Rock Springs Capital Management, LP | 3.42% | 751,889 | 5.35M | Dec 30, 2022 |
| Trium Capital Llp | 3.09% | 679,744 | 4.84M | Dec 30, 2022 |
| Atlas Venture Life Science Advisors, LLC | 2.73% | 599,524 | 4.27M | Dec 30, 2022 |
| Atlas Venture Advisors, Inc. | 2.62% | 574,996 | 4.09M | Dec 30, 2022 |
| DAFNA Capital Management, LLC | 2.62% | 576,881 | 4.11M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.30% | 285,564 | 2.03M | Sep 29, 2022 |
| Russell Inv Co-U.S. Small Cap Equity Fund | 0.78% | 171,649 | 1.22M | Oct 30, 2022 |
| Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 0.75% | 165,000 | 1.17M | Sep 29, 2022 |
| Russell Inv Co- Tax-Managed U.S. Mid & Small Cap Fund | 0.56% | 123,608 | 880.09K | Oct 30, 2022 |
| Fidelity Extended Market Index Fund | 0.50% | 109,999 | 783.19K | Nov 29, 2022 |
| ETF Opportunities Tr-Formidable ETF | 0.28% | 62,478 | 444.84K | Sep 29, 2022 |